Meldonium (Mildronate) was developed in Soviet Latvia in the 1970s as a cardioprotective drug. It became infamous in 2016 when hundreds of Eastern European athletes — including Maria Sharapova — were banned for using it. It has never been FDA-approved. And it may work against one of the deadliest cancers with no targeted treatment.

Triple-negative breast cancer (TNBC) is aggressive, poorly understood, and still treated primarily with blunt chemotherapy. What makes it interesting metabolically is a paradox: TNBC cells are unusually dependent on importing carnitine from outside the cell, yet they cannot tolerate carnitine flux being disrupted in either direction. We call this a "carnitine addiction" phenotype.

Meldonium is a dual-target inhibitor of carnitine biosynthesis (BBOX1, IC50 ~34–62 µM) and carnitine transport (OCTN2/SLC22A5, IC50 ~62 µM). Standard clinical dosing achieves plasma concentrations of ~68 µM — directly within the therapeutic window for both targets. It comprehensively depletes cellular carnitine.

DepMap CRISPR screening across 53 breast cancer cell lines shows TNBC models are selectively dependent on SLC22A5 for survival (p=0.028). This dependency correlates near-perfectly with paradoxical levocarnitine sensitivity (r=0.926, p=0.024) — a relationship that is inverted in non-TNBC models (Fisher p=0.004). TCGA analysis of 1,082 breast cancer patients confirms that the BBOX1/SLC22A5 expression ratio is 27-fold elevated in Basal-like tumors but carries no prognostic value — making it a pure predictive biomarker for treatment response, not disease aggressiveness.

Hypothesis: In TNBC stratified by SLC22A5 dependency and carnitine sensitivity, Meldonium pre-treatment will synergistically enhance carboplatin and paclitaxel cytotoxicity by exploiting this carnitine addiction phenotype. A comprehensive literature search confirms zero published combination therapy studies linking Meldonium to any cancer treatment — an extraordinary gap given 50 years of clinical use in Eastern Europe.

The drug is cheap, off-patent, and its human safety profile is well-established. The scientific rationale is strong. It just never got a fair hearing in the Western oncology system because it could not be patented.